TP53 accumulation in human primary breast carcinomas was studied by a quantitative luminometric immunoassay (LIA), and TP53 gene alterations, exons 5-8, were examined by single* strand conformation polymorphism (SSCP) analysis. In 48 of 142 breast tum or samples, a TPS3 gene alteration was identi* fied. In tum or samples without a TPS3 gene alteration, the median cytosolic TP53 protein level, as determined by LIA, was 0.4 ng/mg protein (range 0-70.8 ng/mg protein), whereas the median TP53 protein level for tumor samples with a TP53 gene alteration was 10 times higher, i.e., 4.1 ng/mg protein (range 0.1-176.0 ng/mg protein). Despite a significant correlation between the outcome of LIA and SSCP, a disagreement was found in 22% of cases analyzed. Significant correlations w ere found between TP53 protein accumulation and low estrogen receptor content, and with a shorter relapse-free as well as overall survival, with a median duration of follow-up of 100 months. Due to its rapid and easy performance on routinely prepared cytosols, the LIA for TP53 protein may be useful in evaluating the prognostic impact of TP53 protein accumulation in human primary breast cancer.
More than 90% of the TP53 gene mutations in tumor cells appear to be confined to the phylogeneticaliy conserved exons 5-8. Except for stop codon mutations and deletions, leading to the expression of a truncated protein, these mutations give rise to a conformationally altered protein, which is due to a prolonged half-life, often stably expressed at high levels (Hollstein et al, 1991; Lane, 1994). The mutated TP53 protein forms oligomeric complexes with the wild-type protein and, as a consequence, can abrogate its normal function. Likewise, wild-type TP53 protein can be inactivated by binding to viral oncoproteins, such as adenovirus E1B and human papillomavi rus E6 proteins. An additional mechanism for inactivation of wild-type TP53 which occurs relatively common in breast cancer is loss of heterozygosity involving the TP53 gene locus. Furthermore, the heterologous interaction of the murine 
Patients and tumor samples
The present study includes 142 human primary breast tumor specimens, used for routine steroid hormone receptor analysis. All clinical data, including age, menopausal status, tumor size, lymph-node status, differentiation grade and steroid hormone receptor status, were available for 111 patients and are shown in Table I •Percentage of cases with TP53 protein expression above the cut-off point (>2.5 ng/mg protein)-2NS, not significant3Numbers do not always add up to i l l due to missing information4Cut-off points: 10 fmol/mg protein.
subsequently amplified by PCR using primer panels flanking exons 5-8 of the TP53 gene (Clontech, Palo Alto, CA). SSCP analysis was performed as described by Orita et al (1989) . Mutations found by PCR-SSCP analysis were confirmed in an additional experiment with a second independent PCR prod uct. Neutral polymorphism in PCR fragments from exon 6 (codon 213) was verified by PCR-SSCP and Taql restriction analysis.
LIA
TP53 protein levels in cytosols were determined using a novel LIA from Sangtec Medical (Bromma, Sweden), as described by Borg et al. (1995) . The assay was performed on an LIA-MAT S300 analyzer (Stratec, Dietzenbach, Germany), equipped with a pipetting station, incubator, washer and luminometer. In brief, either 100 jjlI standard (range 0-80 ng TP53 protein /ml) sample or control and 100 pi tracer (ABEIconjugated monoclonal antibody [MAb] D O l [21] ) solution were pipetted into tubes coated with pAB1801 MAb (Banks et al., 1986) . After incubation for 18 hr at room temperature, tubes were washed 3 times with 2 ml 0.9% sodium chloride, and chemiluminescence was subsequently measured using an LIA-MAT starter service kit (Byk-Sangtec Diagnostica, Diet- 
Statistical analysis
To study relations between patient and tumor characteris tics and TP53 protein, we used Spearman rank correlations when variables were continuous and Kruskal-Wallis or Wilcoxon rank sum for categorized variables. Isotonic regression analysis was performed to determine the optimal cut-off level for TP53 expression (Barlow et al, 1972) . For comparison of the results of both PCR-SSCP and LIA, the 2-sample Wilcoxon rank sum test was applied. Overall and relapse-free survival probabilities were calculated by the actuarial method of Kaplan and Meier (1958) . The Cox proportional hazard model was used for univariate and multi-variate survival analyses.
RESULTS

TP53 protein expression analysis by LIA
LIA for TP53 protein was performed on 142 primary breast tumor cytosols. TP53 protein concentrations ranged from 0 to 176.0 ng/mg protein, with a mean value of 5.8 ng/mg (SD 19.2 ng/mg) and a median value of 0.5 ng/mg cytosolic protein. Cox univariate regression analysis using logarithmically trans formed T P 53 protein values showed a significant (p < 0.001) positive association between TP53 protein concentrations and rate of relapse. This justified the search for cut-off points to classify tumors as TP53 protein-low and TP53 protein-high (accumulated). Different cut-off values were tested for their ability to identify a subgroup of patients with TP53 accumula tion and poor prognosis. Isotonic regression analysis was applied with relapse-free survival as the end-point for all tumor samples (Table II) , and a cut-off point was found at 2.5 ng/mg protein to discriminate between TPS3 protein-high (28%) and TP53 protein-low (72%) cases.
Comparison o f LIA and SSCP
In 48 of 142 breast tumor samples (34%), a TP53 gene alteration was identified by PCR-SSCP analysis. An autoradio gram of SSCP analysis of exon 8 of the TP53 gene is shown in Figure 2 . In 9 tumor samples, the TP53 gene mutation was demonstrated to be confined to exon 5, in 6 samples a mutation in exon 6 was detected and another 9 samples showed a mutation in exon 8. Mutations were most frequently observed in exon 7 (20 samples; Table III) . One breast tumor sample was shown to contain 2 mutations, 1 in exon 5 and the other in exon 6, whereas 3 other samples had alterations in both exons 6 and 8.
Mutations in the TP53 gene were compared with TP53 protein levels as determined by LIA in the same tumor samples, using the cut-off point of 2.5 ng/mg protein. In 111 cases (78%), an agreement was found between the outcome of the LIA test and SSCP analysis: in 83 tumor samples without a TP53 gene alteration, TP53 protein levels were below 2.5 ng/mg protein, and in 28 samples with a mutated TP53 gene, elevated TP53 protein concentrations (> 2.5 ng/mg protein) were measured. A different outcome was observed in 31 cases (22%); Le.t 11 samples without a gene alteration had high levels of TP53 protein and 20 samples with a gene alteration were shown to contain low TP53 protein levels.
In the 94 tumor samples without a TP53 gene alteration, TP53 protein levels ranged from 0 to 70.8 ng/mg protein (Table III) . In samples with a mutation in the TP53 gene, TP53 protein concentrations varied from 0.1 to 176,0 ng/mg protein and the median value was approximately 10 times higher, i.e., 4.1 ng/mg cytosolic protein (Table III) . Using the 2-sample Wilcoxon rank sum test, median TP53 protein concentrations differed in tumor samples with and without a TP53 gene alteration (p = 0.0001).
TP53 protein expression vs. affected exon
Next, TP53 protein levels were investigated as a function of the mutated exon, analyses being confined to exons 5-8 (Table  III) . Cytosols from tumor tissues with a known alteration in exons 5-7 were quantitated to contain 2.0, 3.4 and 3.3 ng/mg protein (median values), respectively. Samples with a mutation in exon 8 contained the highest TP53 (median) protein levels, i.e., 6.0 ng/mg protein (Table III) . In the 4 samples with 2 independent mutations; median TP53 protein concentration was 1.2 ng/mg (range 1.2-5.9 ng/mg; data not shown). Except for exon 5, the differences between TP53 protein levels in samples with a mutation in a specific exon and without a TP53 gene alteration were statistically significant (p < 0.05), as analyzed by the Wilcoxon rank sum test (p values corrected for multiple comparisons). High TP53 protein levels (65.0 ng/m g protein) were measured in the T-47D cell line, which contains a mutated TPS3 gene. In contrast, cytosol prepared from the ZR-75.1 cell line, with wild-type TP53, showed median cyto solic TP53 protein levels (0.4 ng/mg protein; data not shown).
TP53 expression in uni-and multi-vanate prognostic analyses
No significant associations of TP53 protein over-expression with age, menopausal and nodal status, tumor size or pro g ester one receptor status were observed. High TP53 protein levels were more frequently observed in tumors with low estrogen receptor content (p = 0.03).
In univariate analyses, both TP53 gene alteration and TP53 protein over-expression were significantly associated with in creased rates of relapse (p = 0.013 and p < 0.001, resp ec tively; Fig. 3 , top panels) and of death (p -0.026 and p < 0.0001, respectively; Fig. 3, bottom panels) . In this p atien t group, tumor size and low progesterone receptor content w ere also associated with an increased rate of relapse (p = 0.001 and/? = 0.03, respectively). In multi-variate analyses, including age, menopausal status, tumor size, nodal status and estrogen and progesterone receptor status, TP53 protein over-expres sion (either dichotomized or as a continuous variable) was independently associated (p < 0.01) with poor prognosis (Table IV) . Relative relapse and death rates (with 95% confidence limits) were 2.38 (1.34^.23) and 2.99 (1.57-5.68), respectively.
DISCUSSION
In the present study TP53 protein expression levels, as measured with a quantitative immunoassay, were com pared with the prevalence of TP53 gene alterations, as detected by SSCP analysis, in the same 142 breast tumor samples. In 34% of tumor samples, a TP53 gene alteration in exons 5-8 was identified. This value falls within a range of frequencies (17-46%) reported earlier for TP53 mutations in prim ary breast carcinomas (Runnebaum et aL, 1991; O sborne el al, 1991), Samples with a TP53 gene mutation may give rise to a protein with a highly stabilized conformation and, conse quently, an increased half-life as compared with wild-type TP53 protein (Levine et al., 1991) . Using a cut-off point of 2.5 ng/mg protein, high cytosolic levels of TP53 protein w ere observed in 28% of samples analyzed. Borg et al. (1995) , who used the same LIA, found a lower cut-off value, b u t both studies showed TP53 protein over-expression in 30% of tumors. A significant correlation (p -0.0001) was found between TP53 protein over-expression and the presence o f a TP53 gene alteration (exons 5-8). The highest (m edian) TP53 protein level was found for tumor samples harboring a m u ta tion in exon 8 (but numbers are small). Interestingly, the high TP53 protein concentrations measured in cytosols p rep ared from the T47D cell line, which contains a mutated TP53 gene, clearly reflect the elevated TP53 mRNA expression observed on N orthern blots (not shown). The low levels observed in the cytosol from the ZR-75.1 cell line correspond to the presen ce of the wild-type TP53 gene and, consequently, the low m R N A expression levels in the cells.
When dichotomized, a discrepancy was found betw een the results of both assays in 22% of the cases analyzed. T h e difference observed in 20 of 48 cases designated as being TP53 protein-low and TP53 gene-altered by SSCP analysis could be explained by mutations that do not lead to either stabilization of the protein or accumulation in the cells. As suggested previously, the level of TP53 protein expression may be dependent on the type of mutation of the TP53 gene (B o d n er 'N um ber of cases.-2Cut-off point set at 2.5 ng/m g p ro tein .-3M utations in exons 5-8; 4 samples were shown to contain 2 m utations (see " R esults" ).
et cii, 1992), which is not disclosed by the SSCP analysis in this study. SSCP-positive tumors may include those with silent mutations as well as those with stop codons and deletions leading to expression of truncated protein, which is undetect able by immunological techniques (Greenblatt e/ al, 1994). We have therefore sequenced DNA from 14 DNA samples avail able out of the 20 SSCP-positive/LIA-negative samples. Of these, 4 samples showed deletions or insertions leading to an altered protein product. All 4 samples had low levels of protein. The other 10 DNA samples showed a silent mutation. Of these, 1 sample showed an elevated LIA level, another sample showed an LIA level of 2.5 ng/mg protein (cut-off point) and the remaining 8 samples showed low LIA levels, meaning that 12 of 14 were concordant. So far, it is not clear from our data that LIA will detect mutations of particular prognostic interest according to the data of Bergh et al (1995) or Borresen et al. (1995) . Furthermore, proteins of viral origin, e.g., E6 oncoprotein, may target the TP53 protein to more rapid catabolism (Greenblatt et al., 1994) , which leads to low TP53 protein levels.
The 11 cases (of 39) assigned as TP53 protein-high and not altered according to SSCP (28%) could be explained by the accumulation of TP53 protein in cytosols due to stabilization of the wild-type protein when forming complexes with other cellular or viral molecules. In these cases, accumulated wildtype TP53 protein would also be detected by the immunoassay since the LIA test utilizes MAbs specific for denaturationresistant epitopes of the NH2-terminus of the protein, thus recognizing both mutant and wild-type TP53 proteins. More over, mutations may be present in other exons or introns or even in the regulatory gene sequences outside the regions screened by SSCP analysis, giving rise to high levels of TP53 expression without evidence of a mutation. However, only a small percentage (below 10%) of the reported mutations have been found outside of exons 5-8 (Greenblatt et a l 1994) . Another explanation could be accumulation of TP53 protein because of recent DNA damage from chemical and physical genotoxic agents (Greenblatt et al., 1994) . Obviously, the cut-off point itself, selected because of the correlation of relapse-free survival with TP53 protein over-expression and Relative hazard rates with 95% confidence limits (values in parentheses) are presented for the variables with p < 0.10 in the multivariate analysis.-2Tumour size scored as T 1 -T 4 -3As compared to node-negative.~4Receptor-positive as compared with receptor-negative (cut-off points, 10 fmol/mg protein)-5TP53 protein expression above 2.5 ng/mg protein as compared with TP53 protein levels below the cut-olfvalue. not with prevalence of TP53 gene mutations, also affects the agreement between the results of both assays. Nevertheless, the overall correlation between the outcome of both assays is highly significant (p = 0.0001).
With respect to prognosis, TP53 protein accumulation appeared to be an independent predictor for both relapse-free survival and death. These findings complement the results of both DNA-based and immunohistochemical investigations, which showed a strong association between either TP53 gene alteration or TP53 protein accumulation and poor prognosis (Elledge et a l, 1994; Andersen et aL> '1993; Boer et al.} 1995 (Greenblatt et aL, 1994) . In contrast, SSCP, CGGE and DGGE analyses have a sensitivity and specificity of approxi mately 90% (Greenblatt et al, 1994 ) but are time-consuming and labor-intensive. The immunoassay applied in this study is easier and faster to perform and can be carried out on breast tumor cytosols routinely prepared for steroid hormone recep tor assays. Moreover, the immunoassay objectively quantitates TP53 protein expression, TP53 protein levels apparently being a reasonably good representation of both mutant and wild-type TP53 DNAs. Quantitative analysis of the TP53 protein status in cytosols routinely prepared for steroid hormone receptor analysis may contribute to the selection of patients who, depending on the relationship of TP53 gene status with response to a specific type of systemic adjuvant therapy, could benefit from adjuvant therapy.
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